Avicanna announces sponsorship of Phase II study on osteoarthritis pain

Avicanna (AVCNF) entered into a Sponsored Research Agreement to sponsor an investigator initiated study on “The Effectiveness of Oral Cannabis Extracts for Osteoarthritic Pain: An Internal Pilot, Placebo Controlled, Blinded Randomized Multicentre Trial”. The RCT is led Hance Clarke, MD, FRCPC, PhD as the principal investigator who is the medical director of the Pain Research Unit, and a clinician at University Health Network and is anticipated to start in the Fall of 2025. The primary objective of the RCT is to determine the feasibility of a blinded, randomized, placebo-controlled, 3-arm, parallel group trial of oral cannabinoids for improving pain interference in patients with hip and/or knee osteoarthritis. Specifically, the RCT will look to discover whether the planned definitive RCT is feasible with respect to patient enrollment, protocol adherence, and data completeness. The RCT is funded by a Canadian Institutes of Health Research grant and is sponsored by Avicanna that is providing its proprietary CBD and THC capsules produced under Good Manufacturing Practices for the trial.